Amgen's Parasabiv Rejected by FDA
News Aug 26, 2016
Amgen has announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the New Drug Application (NDA) for Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
The correspondence of a Complete Response Letter means that the FDA has decided that they will not approve Parsabiv in its present form.
Amgen is reviewing the Complete Response Letter, and anticipate a post-action meeting with the FDA later this year to discuss the Complete Response.
Amgen claim that the Complete Response Letter does not impact their regulatory submissions in other regions.
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019
23rd World Congress on Pediatrics, Neonatology & Primary Care
Nov 22 - Nov 23, 2019